<DOC>
	<DOCNO>NCT01280526</DOCNO>
	<brief_summary>This study open label , multicenter study two phase : - A dose escalation phase Romidepsin administer IV day 1 8 day 1 without day 8 combination cyclophosphamide , doxorubicin , vincristine prednisone ( CHOP ) administer every 3 week 8 cycle patient T-cell lymphoma . - An expansion phase order ass safety efficacy association recommend dose Romidepsin associate CHOP population patient T-cell lymphoma .</brief_summary>
	<brief_title>A Study Escalating Doses Romidepsin Association With CHOP Treatment Peripheral T-Cell Lymphomas</brief_title>
	<detailed_description>The primary objective study determine feasibility combination recommend dose ( RD ) Romidepsin administer association CHOP population patient newly diagnose Peripheral T-cell lymphoma ( PTCL ) measure toxicity treatment . Secondary objective : - To assess safety association Romidepsin CHOP , - To assess efficacy association Romidepsin CHOP : response rate complete response rate , progression-free survival , response duration overall survival .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>1 . 1 . Patients histologically confirm Peripheral Tcell Lymphoma ( PTCL ) , previously treat ; subtypes may include except HTLV1related Tcell lymphoma , cutaneous Tcell lymphoma ( mycosis fungoid Sézary syndrome ) , ALK+ PTCL , 2 . Ann Arbor stage II IV 3 . Aged 18 80 year , 4 . ECOG performance status 0 , 1 2 , 5 . Signed informed consent , 6 . Negative pregnancy test female childbearing potential ( FCBP ) , 7 . FCBP use effective method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide abstinence ) treatment period 1 month thereafter ; Males use effective method birth control treatment period 3 month thereafter , 8 . Life expectancy ≥ 90 day ( 3 month ) 2 . 1 . Other type lymphoma , e.g . Bcell lymphoma 2 . Ann Arbor stage I 3 . Previous treatment PTCL immunotherapy chemotherapy except shortterm corticosteroid inclusion 4 . Previous radiotherapy PTCL except localize one lymph node area 5 . Central nervous system meningeal involvement 6 . Contraindication drug contain chemotherapy regimen 7 . HIV infection , active hepatitis B C 8 . Any serious active disease comorbid medical condition ( accord investigator 's decision ) 9 . Any following laboratory abnormality Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) , Platelet count &lt; 100,000/mm3 ( 100 x 109/L ) , 75,000 bone marrow involve , Serum SGOT/AST SGPT/ALT ≥ 5.0 x upper limit normal ( ULN ) , Serum total bilirubin &gt; 2.0 mg/dL ( 34 µmol/L ) , except case hemolytic anemia , Low K+ ( inferior low normal level ) low Mg+ ( inferior low normal level ) level , except correct beginning chemotherapy , 10 . Use oral contraceptive contraceptive patch , 11 . Calculated creatinine clearance ( CockcroftGault formula ) &lt; 50 mL /min , 12 . Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless subject free disease ≥ 3 year , 13 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form , 14 . Left Ventricular Ejection Fraction &lt; 45 % ( calculated echocardiographic scintigraphic method ) , 15 . Patients congenital long QT syndrome , history significant cardiovascular disease and/or take drug lead significant QT prolongation , 16 . Corrected QT interval &gt; 480 msec ( use fridericia formula ) 17 . Use standard experimental anticancer drug therapy within 28 day initiation ( Day 1 ) study drug , 18 . Pregnant lactate female woman childbearing potential willing use adequate method birth control duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>